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We have introduced two endoscopic treatments for early gastric cancer: endoscopic
mucosal resection using a cap-fittedpanendoscope (EMRC),and endoscopic lasertherapy
using a Nd-YAG laser. Thirty-two patients (34 lesions) with gastric cancer were treated
by Nd-YAG laser; including 23 initial-therapy cases (25 lesions) and 9 second-therapy
cases representingfailmes ofendoscopicmucosal resection or endoscopic ethanol injection.
Endoscopic laser therapy was performed safely without complication in all patients.
Three patients had residual cancer, and 2 of these required surgery. Six patients died
from other disease. Endoscopic laser therapy can remove early gastric cancer even when
the lesion has ulceration or submucosal invasion, and has a powerful hemostatic effect.
It is a safe and effective treatment for early gastric cancer.
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INTRODUCTION
Neodymium yttrium aluminum garnet (Nd-YAG) laser
treatment has been used to alleviate obstruction from
unresectable malignant lesions of the gastrointestinal
tract [1], to arrest hemorrhage from gastric vascular
ectasia [2],and to treat early gastric cancer curatively [3].
Curative endoscopic treatment for early gastric cancer
has become accepted at many institutions in Japan,
incorporating such specific modalities as polypectomy,
mucosal resection (EMR), laser, heatprobe, microwave,
injections and hyperthermia. We have introduced two
endoscopic treatments for early gastric cancer. The
first is an endoscopic mucosal resection using a
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cap-fitted panendoscope (EMRC) [4-6].The second is
a laser therapy using a medical Nd-YAG laser system
(MC2100) [7].
We examined our results with endoscopic laser
therapy and evaluated its role in the endoscopic
treatment of early gastric cancer.
MATERIALS AND METHODS
Indication
Absolute indications for endoscopic treatment of eariy
gastric cancer were well-differentiated tubular
adenocarcinoma and type 0’IIa smaller than 20mm in
diameter or type 0’IIb or 0’IIc smaller than 10 mm in
diameter without ulcer or ulcer scar. Relative indications
for treatment were inoperable tumors in patients who
were poor surgical risks or who refused surgery. The
macroscopic type of early gastric cancer was assessed
according to the Japanese Classification of Gastric
Carcinoma [8].
Table Thirty-two cases of 34 gastric tumorous lesions were
treated by Nd-YAG laser system MC2100 fron August 1987
September 1995.
Male: Female
Mean age
Location
Macroscopic
type
28:4
Male: 75 (58--,74) Female: 76 (60--88)
m.w.
L.C.
EW.
G.C.
Lower Middle Upper
3 2 0
6 8 5
3 3 2
0 0 2
5
19
8
2
12 13 9 34
adenoma 4 0IIc 6
0IIa 9 0IIc+IIa 4
0I after EMR 6
0IIa+IIc after ethanol injection 3
A.W. anterior wall
L.C. lesser curvature
EW. posterior wall
G.C. greater curvature
Patients
Thirty-two patients with 34 lesions ofearly gastric tumor
were treated by endoscopic Nd-YAG laser irradiation
fromAugust 1987 to October 1995. Of 32 cases of laser
therapy, 23 cases (25 lesions) were initial-therapy cases.
Nine cases were second-therapy cases, representing
residual tumor followingEMR (6 lesions) or endoscopic
ethanol injection (3 lesions). Of 23 initial-therapy cases,
15 (16 lesions) were absolute indication lesions (adenoma:
4 lesions, type 0’IIa: 71 lesions, type 0’IIc: 5 lesions).
Eight cases (9 lesions) were relative indication lesions
(type 0’IIa: 2 lesions, type 0’I: 1 lesion, type 0’IIa + IIc:
1 lesion, type 0’IIc: 1 lesion, type 0’IIc + IIa: 4 lesions).
Table 1 shows the characteristics ofpatients and lesions.
There were 28 men, ranging in age from 58 to 84
(mean, 75) years and 4 women, ranging in age from 60
to 88 (mean, 76) years. In all cases, ahistological diagnosis
was obtained from examination of biopsy specimens.
Location and macroscopic type were assessed by
endoscopic findings. Follow-up period ranged from one
to 98 months. FIGURE Medical Nd-YAG laser system MC2100.Nd-YAG LASER FOR EARLY GASTRIC CANCER 205
FIGURE 2a An EMRC cap (transparent plastic hood).
Methods
We used a medical YAG laser system MC2100
(Technomedical International Corp., France; Fig. 1)
which has a 1.32-tm wavelength in addition to the
conventional 1.06-m wavelength. The 1.32-tm
wavelength is more highly absorbed by living tissues
than the 1.06-tm wavelength. Thus, endoscopic laser
irradiation can be performedmore safely and effectively
with lower output using the 1.32-m wavelength. In
most cases we selected a 1.32-tm wavelength,
20 watts of output, continuous wave, and the non-
contact method.
We performed laser irradiation using a transparent
EMRC cap as Ozaki’s method [9]. An EMRC cap
(transparent plastic hood; Fig. 2a) was fitted to the tip
ofthe endoscope and the laser fiber was passed through
the biopsy channel (Fig. 2b). Using the cap, we obtained
a good view in a variety of lesion sites and maintained
the necessary distance between the laser fiber and the
lesion during irradiation.
Follow-up
We medicated all patients with H2-blockers and
sucralfate (mucosa-protecting drugs) for 1 month after
treatment. Endoscopic examination and pathological
examination of biopsy specimens were performed 1,
3, 6, 9 and 12 months after treatment, and then twice
a year.
FIGURE 2b An EMRC cap (transparent plastic hood) is fitted to
the tip of the panendoscope, and the laser fiber is passed through
the biopsy channel.
RESULTS
Twenty-four in 32 patients were treated on an
ambulatory basis with endoscopic laser therapy. Eight
patients were treated as inpatients. Fifteen of the 34
lesions were laser-irradiated once, and 19 lesions were
irradiated more than once. Two patients with a total of
these lesions had laser therapy because EMR was
contraindicated. One was a patient with a pacemaker
for whom it was not safe to use high-frequency
electr0cautery, and another was a hemodialysis patient
with liver cirrhosis and hypocoagulability.206 1V TANI et al.
FIGURE 3a Residual cancer after endoscopic mucosal resection
located on the lesser curvature of the upper body of the stomach
is detected in the biopsy specimen from the small reddish area of
the scar.
FIGURE 3c Endoscopic examination performed 6 months after
treatment shows scar without residual disease.
Complications
We experienced no complications in 32 cases of
endoscopic laser therapy using the medicalYAG laser
system MC2100.
FIGURE 3b Laser irradiation is performed using an EMRC cap
with the MC2100.
Illustrative Case
Figure 3 shows a case of residual cancer following
EMRC in a 72-year-old man.A biopsy specimen from
a small reddish area of the edge of the scar revealed
adenocarcinoma (Fig. 3a). We performed endoscopic
laser irradiation using anEMRC cap with theMC2100
(non-contact method, continuous wave, 1.32-1xm
wavelength, 20 watts, and 510 joules). Because the
lesion was located in the upper gastric body on the
lesser curvature, only an oblique view of the lesion
was obtained by usual endoscopic examination. The
EMRC cap at the tip of the endoscope allowed a front
view of the lesion, and vertical laser irradiation was
performed (Fig. 3b). The patient was cancer-free 27
months following laser therapy (Fig. 3c).Nd-YAG LASER FOR EARLY GASTRIC CANCER 207
Table II Outcome of 32 cases of 34 gastric tumorous lesions treated by Nd-YAG laser therapy
23 cases
(25lesions)
9 cases
(9lesions)
13 cases ---
(14lesions)
[’-’1 15 cases
/I (161esions) .
/’ "i cas;S
/
(21esins)
! 4 cases
4 cases
(4lesions)
13 cases
(14lesions)
3 cases
(4lesions)
1 case
(1lesion)
7 cases
(7lesions)
2 cases
(2lesions)
Outcome
Table II shows the outcome of 32 cases (34 lesions) of
gastric tumor treated by endoscopic laser therapy using
the medical YAG-laser system MC2100. Twenty-six
patients are living, of which 23 are cancer-free. Of
three patients with residual cancer, two required surgery
and one is undergoing additional laser therapy at the
time of this writing. Six patients died from intercurrent
disease.
One of the two operative cases was an 80-year-old
man with residual cancer following EMR at another
center. Cancer remained following five treatments with
laser therapy; we therefore performed a gastric
resection. Macroscopic findings in the resected stomach
were a small tumor in the whitish area (Fig. 4a).
FIGURE 4a Resected stomach.208 M. TANI et al.
FIGURE 4b Almost all of the submucosal layer in the irradiated
area is replaced by fibrosis.
Histological examination ofthe irradiated area revealed
cancer cells remained in the mucosal layer. Almost all
of the submucosa was replaced by fibrosis (Fig. 4b).
DISCUSSION
Endoscopic laser therapy has several roles in the
treatment of gastric cancer including alleviation of
stenosis in advanced cases, hemostasis, and curative
treatment in early disease.
Gastric mucosal cancers rarely demonstrate lymph
node metastasis, and it is widely accepted in Japan
that small gastric mucosal cancers withoutlymph node
metastasis can be curatively treated endoscopically.
Single early gastric cancers resected at our department
were retrospectively analyzed with regard to the depth
of invasion and the incidence of lymph node meta-
stasis [10]. From this we determined our absolute
indications for endoscopic treatment. Curative
treatment is possible for lesions of well-differentiated
tubular adeno carcinoma and type 011a smaller than
20 mm or type ORb or 0IIc smaller than 10 mm
without ulcer or ulcer scar. Relative indications for
treatment are inoperable tumors secondary to poor
risk factors or refusal of surgery.
Endoscopic mucosal resection (EMR) allows more
accurate histopathological analysis than other
endoscopic treatments. Using our modified EMR
procedure (EMRC), large specimens can be obtained
and lesions that are located on the lesser curvature or
posterior wall of the body of the stomach, which are
ditYlcult to resectby conventionalEMR, canbe resected
completely with ease.
Fifty-seven patients with 68 lesions of early gastric
tumor were treated by EMRC procedure from August
1992 to October 1995. In 57 cases of EMRC, we
experienced 3 cases of muscular resection and 5 cases
of bleeding. Of 57 patients, 56 are living. One died
from intercurrent disease. Two patients had residual
tumor and required additional laser therapy. Two
patients required surgery. Fifty-four of our 57 patients
having EMRC were treated as inpatients.
Safe and sufficient mucosal resection cannot be
performed when the lesion has fibrosis from an ulcer
or an ulcer scar, because the involved mucosa cannot
be separated sufficiently from the muscular layer by
injecting saline solution into the submucosa. EMR
specimens usually containmucosa and the middle layer
of the submucosa. The deep layer of the submucosa
cannot be resected. Gastric cancer invading into or
beyond the middle ofthe submucosa cannotbe resected
curativdy and contraindicates EMR.Thus, early gastric
cancer with an ulcer or an ulcer scar or invasion into
the middle or deeper layer of the submucosa are
contraindications to EMR.
With laser therapy, locally curative treatment for
early gastric cancer can be obtained even when the
lesion has fibrosis or submucosal invasion. The role of
endoscopic lasertherapy in patients with gastric cancer
and advanced age or severe complications has been
reported [11-13]. Endoscopic laser therapy has several
advantages as a treatment for early gastric cancer in
these cases.
First, endoscopic lasertherapy is powerful and almost
the full thickness of the submucosa can be irradiated
depending on the laser output and the duration, so
locally curative treatment can be obtained even when
the lesion invades into the middle or deeper portion of
the submucosa.
Second, endoscopic laser therapy rarely causes
complications such as bleeding, perforation, or stenosis.Nd-YAG LASER FOR EARLY GASTRIC CANCER 209
Table III Strategy of endoscopic treatment for early gastric cancer. (First Dept. of Surg. TMDU)
EMRC
Laser
Laser
Laser
ul(+):
NRC:Endoscopic Mucosal Resection/lesionsCap’fittedwithPanendscPeulcer or ulcer scar Laser /
M: cancer limitted to the mucosa
The overall complication rate of laser endoscopy in
1859 cases of gastrointestinal cancer in Tajiri’s series
was 2.9% [14]. The most frequent complication was
bleeding, reported in 45 patients (2.4%), followed by
perforation in 5 patients (0.3%) [14]. In our series we
experienced no complications.
Third, laser therapy has a powerful hemostatic effect,
and patients with clotting deficiencies can be safely
treated.
Fourth, features of the medical YAG-laser system
MC2100 make laser irradiationcan particularly safe and
effective. Because 1.32-m wavelength is absorbed by
water ten times as much as the conventional
1.06-m wavelength, effective irradiation to living tissue
is available with lower output (10 to 30 watts compared
to 50~70 watts respectively; see reference [15]).
Fifth, hospitalization is not necessary.
AnEMRC cap is useful for diagnosis, resection, and
hemostasis during EMR of gastric lesions. Using an
EMRC cap, front views with adequate distance from
the lesions in any location can be obtained, and the
lesions can be measured relative to the diameter of the
cap. Thus, precise assessment of lesions and accurate
mucosal resection and hemostasis can be performed.
In endoscopic laser therapy, an EMRC cap permits
vertical irradiation with adequate distance between the
laser fiber and the lesion.
One problem with endoscopic treatment is an
inability to diagnose the stage of a lesion. It is
particularly very difficult to diagnose the spread of
undifferentiated adenocarcinoma. For those lesions,
we perform four or more biopsies of normal mucosa
surrounding the lesion and record the biopsy locations.
During laser irradiation, we make marks surrounding
the lesion based on the histological results of these
biopsies, and irradiate an area of mucosa that
encompasses all the marks. We hypothesise that this
method will reduce the incidence of residual cancer.210 IV[ TANI et al.
In conclusion, we have found that endoscopic laser
therapy can be performed on an outpatient basis. It can
remove early gastric cancer even when the lesion
includes an ulcer, scar, or submucosal invasion, and it
has a powerful hemostatic effect. This therapy is a safe
and effective treatment for early gastric cancer including
lesions in poor surgical candidates and residual lesions
following other endoscopic treatments.
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